-
Jiangsu QYuns Therapeutics Plans IPO on Hong Kong Stock Exchange
•
China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has announced its intention to pursue an initial public offering (IPO) on the Hong Kong Stock Exchange, although specific pricing and additional details remain undisclosed at this time. This strategic move aims to enhance the company’s visibility and funding capabilities in the…
-
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
•
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data this week from trials assessing the efficacy of IL-23 blockers, Tremfya (guselkumab) and JNJ-2113, in the treatment of psoriasis. The findings, derived from a late-stage study, reveal that Tremfya facilitated clear skin within 28 weeks…
-
MicroPort Secures Market Approvals for ULYS ICDs and INVICTA Leads in Japan
•
Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device…
-
Hainan Implements New Regulations for Import Drugs and Medical Devices in Medical Tourism Zone
•
The Hainan Medical Products Administration, in conjunction with Hainan’s Health Commission Bureau, has unveiled a comprehensive set of measures to regulate the import of urgently needed drugs and medical devices for use outside of hospitals within the Hainan Boao Lecheng International Medical Tourism Pilot Zone. This initiative aims to streamline…
-
Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research
•
Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking a significant step in the company’s commitment to advancing research in this innovative field. The new facility, spanning 9,290 square meters, represents a substantial investment of $250 million and enhances Bayer’s biotechnology network, which includes…
-
AstraZeneca Seeks Approval for Capivasertib in Combination with Faslodex for Breast Cancer Treatment
•
AstraZeneca (AZ, NASDAQ: AZN) has submitted a market approval filing for its Category 1 drug candidate, capivasertib, in combination with Faslodex (fulvestrant), according to the China Center for Drug Evaluation (CDE) website. The filing has been accepted for review, marking a significant step forward in the treatment of hormone receptor…
-
Jiangsu Hengrui Medicine Gets NMPA Approval for Anti-Tumor Drug Candidate SHR-2022
•
Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its investigational drug candidate, SHR-2022 injection. This marks a significant step forward in the development of a new approach…
-
China NT Pharma Group Enters MOU with Global Fund to Expand Orthopedic Product Line
•
China NT Pharma Group Company Ltd (HKG: 1011), a China-based pharmaceutical company, has announced the signing of a non-binding memorandum of understanding (MOU) with the Global New Normal Anti Inflation Limited Partner Fund. This cooperation is aimed at bolstering NT Pharma’s presence in the orthopedic products sector, with the fund…
ADC / XDC AstraZeneca Auto-immune AZ Biotech BMS Bristol-Myers Squibb Cancer CAR-T Cell-therapy Clinical trial approval / initiation Clinical trial results Combination therapy CRO / CMO / CDMO CVD Diabetes Eli Lilly Finance Finanical Reports Gene therapy Hengrui Medicine J&J Johnson & Johnson Market approval filings Merck MSD Multi-specific antibodies NASDAQ: AZN NMPA Novartis NYSE: BMY NYSE: JNJ NYSE: LLY NYSE: MRK NYSE: NVS Obesity Ophthalmology PD-1/L1 Pfizer Potential first-in-class Product approvals Rare / orphan disease drugs SHA: 600276 TKIs (EGFR VEGF BTK etc.) Vaccine
